Imperial College London
Alternate

ProfessorRogerGunn

Faculty of Medicine, Department of Brain Sciences

Emeritus Professor of Molecular Neuroimaging
 
 
 
//

Contact

 

r.gunn

 
 
//

Location

 

Burlington DanesHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Martin:2019:brain/awz120,
author = {Martin, Bastida A and Lao-Kaim, N and Roussakis, A and Searle, G and Xing, Y and Gunn, R and Schwarz, S and Barker, R and Auer, D and Piccini, P},
doi = {brain/awz120},
journal = {Brain},
pages = {2023--2036},
title = {Relationship between neuromelanin and dopamine terminals within the parkinson’s nigrostriatal system},
url = {http://dx.doi.org/10.1093/brain/awz120},
volume = {142},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Parkinson’s disease is characterized by the progressive loss of pigmented dopaminergic neurons in the substantia nigra and associated striatal deafferentation. Neuromelanin content is thought to reflect the loss of pigmented neurons, but available data characterising its relationship with striatal dopaminergic integrity are not comprehensive or consistent, and predominantly involve heterogeneous samples. In this cross-sectional study, we utilised neuromelanin-sensitive magnetic resonance imaging and the highly specific dopamine transporter positron emission tomography radioligand, 11C-PE2I, to assess the association between neuromelanin-containing cell levels in the substantia nigra pars compacta and nigrostriatal terminal density in vivo, in 30 patients with bilateral Parkinson’s disease. Fifteen healthy controls also underwent neuromelanin-sensitive imaging. We used a novel approach taking into account the anatomical and functional subdivision of substantia nigra into dorsal/ventral tiers and striatal nuclei into pre/post-commissural sub-regions, in accordance with previous animal and post-mortem studies, and consider the clinically asymmetric disease presentation. In vivo, Parkinson’s disease subjects displayed reduced neuromelanin levels in the ventral (-30±28%) and dorsal tiers (-21±24%) as compared to the control group (F1,43 = 11.95, P = 0.001). Within the Parkinson’s disease group, nigral pigmentation was lower in the ventral tier as compared to the dorsal tier (F1,29 = 36.19, P < 0.001) and lower in the clinically-defined most affected side (F1,29 = 4.85, P = 0.036). Similarly, lower dopamine transporter density was observed in the ventral tier (F1,29 = 76.39, P < 0.001) and clinically-defined most affected side (F1,29 = 4.21, P = 0.049). Despite similar patterns, regression analysis showed no significant association between nigral pigmentation and nigral dopamine transporter density. However, for the clinically-d
AU  - Martin,Bastida A
AU  - Lao-Kaim,N
AU  - Roussakis,A
AU  - Searle,G
AU  - Xing,Y
AU  - Gunn,R
AU  - Schwarz,S
AU  - Barker,R
AU  - Auer,D
AU  - Piccini,P
DO  - brain/awz120
EP  - 2036
PY  - 2019///
SN  - 1460-2156
SP  - 2023
TI  - Relationship between neuromelanin and dopamine terminals within the parkinson’s nigrostriatal system
T2  - Brain
UR  - http://dx.doi.org/10.1093/brain/awz120
UR  - http://hdl.handle.net/10044/1/68670
VL  - 142
ER  -
Download